DKK1 and bone disorder: Owing to the compensatory effects of DKK1 levels and sclerostin expression, and the therapeutic potential of antibodies that target sclerostin (Scl-Ab) and DKK1 (DKK1-Ab) in treating bone disorders, including for improving fracture healing and increasing bone formation, Florio et al. (2016) proposed that a synergistic effect was triggered by the simultaneous blockage of DKK1 and sclerostin.